Background: Percutaneous atrial septal defect (ASD) closure is a routine procedure
Introduction
Atrial septal defect (ASD) is one of the most frequent congenital heart defects [1] . While the only risk of small ASDs is paradoxical embolism, sequelae of larger ASDs comprise pulmonary hypertension, congestive heart failure, and atrial arrhythmia, in particular atrial fibrillation (AF) [2] [3] [4] [5] . Percutaneous ASD closure is the treatment of choice for ASDs to prevent such adverse outcome and to improve exertional dyspnea [6] [7] [8] . Percutaneous ASD closure is an overall safe procedure but it carries a potential risk for developing AF by device irritation of the septum [9] [10] [11] .
Although such new onset AF typically occurs only in the first few weeks after device implantation [9, 12] , patients undergoing percutaneous closure of large ASDs are temporarily at a double risk for developing AF, 1) due to septal device irritation and 2) due to the preexisting atrial enlargement. Subsequent reduction of atrial diameters after shunt elimination reduces the risk for AF. A net benefit in that respect can be expected but the overall risk for AF of such patients remains elevated. The situation is similar for patients with a patent foramen ovale (PFO) and enlarged atria.
In AF, left atrial appendage (LAA) closure has emerged as an alternative to medical therapy in the form of chronic oral anticoagulation (COA) for stroke or bleeding prevention. While closure of the LAA comes at the price of 2-7% procedural adverse events, it shows a significant reduction in major bleeding events at a similar stroke rate compared to COA [13] [14] [15] [16] . After 4 years of follow-up, closure of the LAA even showed significantly improved survival in randomized comparisons [17, 18] .
Closure of the LAA so far has been exclusively performed in patients with documented AF, either for primary prevention (patients with AF without previous embolic ischemic event or bleeding) or secondary prevention (patients with AF with a previous embolic ischemic event or bleeding).
Percutaneous closure of septal defects, particularly large ASDs, hinders future percutaneous transseptal left atrial access although it remains possible at least in the case of smaller ASD [19] or PFO devices [20] . Even if such patients never had AF, their risk for developing AF during follow-up is 2-fold higher after ASD closure than that of the general population [21] and also increased after PFO closure in the presence of enlarged atria.
Herein reported is the first experience with concomitant percutaneous closure of LAA at the time of closure of ASDs or PFOs in the presence of enlarged atria in patients without history of AF. They were considered at increased risk for later AF, particularly in the initial phase after septal shunt closure due to septal device irritation while atrial dimensions have not yet shrunk after volume unload. It is referred to in this procedure as primary primary preventive LAA closure, i.e., LAA closure for primary prevention (in anticipation of AF or even preventing AF) and for primary prevention of stroke or bleeding, should AF occur.
METHODS

Population
This is a retrospective study of consecutive patients (≥ 40 years) undergoing percutaneous closure of a large ASD (≥ 20 mm) or a PFO with large atria (left atrium (LA) ≥ 40 mm, parasternal long axis) and at the same time of the LAA. Patients neither had clinical or electrocardiographic signs of prior AF nor an AF associated embolic ischemic or bleeding event. In the patients with prior ischemic events, AF had been excluded by long-term electrocardiogram (ECG). Patients consented to both procedures (ASD closure and LAA closure) separately and also to data collection. The potential benefits and risks of primary primary preventive LAA closure was discussed extensively with the patients. The local institutional review boards approved data collection of clinically indicated investigations during follow-up. The procedures were performed at the university hospitals of Bern and Zurich. Demographic and clinical characteristics, including risk for stroke and major bleeding (CHA 2 DS 2 -VASc score, HAS-BLED score), procedural data, and outcome data of in-hospital and follow-up periods were captured from medical records and patient contact.
Procedure
All procedures were performed under fluoroscopy guidance without echocardiography [15, 22, 23] . All patients had had transesophageal echocardiography (TEE) during their workups. Computer tomography was not used.
Oral antibiotics (2-3 doses) were given before and after the procedure and all patients received 5000 units of intravenous heparin at the beginning of the procedure. All Post interventional antithrombotic regimen comprised clopidogrel 75 mg for 1-3 months and acetylsalicylic acid 100 mg for 5-6 months. Control TEE was recommended after 3-6 months to assess for device thrombi and residual shunts or leaks.
Outcome
The composite endpoint was defined according to Valve Academic Research Consortium (VARC)-2 criteria [24] . The primary safety endpoint was defined as death related to closure of the LAA, procedure-related ischemic stroke, hemorrhagic stroke, cardiac tamponade, need for urgent surgery (e.g., due to embolization of the device, repair of procedure-related injury, or bleeding) and major or life-threatening bleeding (according to VARC-2 criteria). The primary efficacy endpoint was defined as stroke (non-disabling, disabling, ischemic, or hemorrhagic), systemic embolization, or cardiovascular or unexplained death. New-onset of AF was looked for clinically and by (24-h) ECG. Clinical follow-up data were obtained reviewing medical records and by contacting patients.
Statistical analysis
Data are expressed as mean and standard deviation for continuous variables and as number and percentage for categorical variables. Analysis was performed using a standard statistical software program (SPSS, version 23; IBM, Armonk, NY, USA).
Results
Baseline characteristics
Thirteen patients were included between April 2013 and June 2015. Patients were 58 ± 9 years old (54% women). Baseline characteristics are described in Table 1 .
No patient had any history of AF. Three patients had a previous history of ischemic cerebrovascular events. The total procedural fluoroscopy time was 16 ± 8 min (Table   2 ).
Device success
In all patients ASD or PFO and LAA closures were successful. In 1 patient 2 ASDs and in 1 patient, a PFO in addition to an ASD were found and closed with 2 separate devices (Figs. 2, 3) .No periprocedural complications occurred (Table 2) .
Clinical follow-up
Length of hospital stay was 1 night in 9 patients and the remaining 4 patients were discharged the same day. TEE follow-up was available after 6.7 ± 2.0 months in 10 patients. No device-related complications occurred (Table 3) . One patient needed a re-intervention because of 2 residual ASD shunts at follow up. Re-intervention was successfully performed under fluoroscopy only using a 25 mm and a 18 mm PFO Occluder at 6 months after initial procedure. At clinical follow-up of 2.0 ± 0.8 years, no adverse events had occurred, no patient had reached a primary safety or efficacy endpoint, and at latest contact 91% of patients were on no anticoagulant or antiplatelet medication and 9% still acetylsalicylic acid ( Table 4 ). The patients were asked for clinical symptoms of AF and all postinterventional ECGs were screened for AF. No patient had developed AF.
Discussion
Atrial fibrillation is the most common sustained cardiac arrhythmia [25] and is associated with substantial mortality and morbidity, particularly due to stroke [26] .
ASD closure is advocated for prevention of stroke (paradoxical or secondary to AF) or heart failure due to volume overload. PFO closure is used for prevention of paradoxical stroke. LAA closure is indicated for prevention of stroke or bleeding in patients with AF [13] [14] [15] [16] [17] [18] .
The present study reports the feasibility and safety of primary primary preventive LAA closure during percutaneous ASD or PFO closure in patients with enlarged atria but no AF. It proved technically successful and safe but efficacy of our approach cannot be determined. No patient developed AF and therefore the potential of preventing embolic ischemia or bleeding because of the obviated need for oral anticoagulation remains unknown.
A large nationwide study of Nyboe et al. [21] included 1168 patients with ASD who were followed-up over a long-term period. The risk of developing AF was up to 10-fold in comparison to the general population. In case of conservative management, the stroke risk was 2.6-fold. In case of ASD closure, the stroke was reduced to 2-fold. This can be due to both, the elimination of paradoxical embolism and the reduction of atrial sizes. Yet, the risk of AF-associated stroke remains elelvated [21] .
Atrial fibbrilation with the need for COA is expected to occur with a certain frequency in patients at some point in time after septal defect closure while they were still in sinus rhythm [9, 27] . Age > 40 years is a well-known risk factor for AF after ASD closure [28] . Moreover, ASD closure devices can trigger new-onset AF in the early phase. In the later phase they may reduce the risk of AF as the atria shrink after elimination of the shunt [10, 11] . Large devices in the interatrial septum may render percutaneous LAA closure intricate or downright impossible.
Chronic oral anticoagulation has been proven to effectively prevent thromboembolic strokes but there is a risk of serious bleeding which deters many patients from taking this therapy [29] . Therefore, alternative treatment options for stroke prevention in patients with AF with increased stroke risk are needed. Closure of the LAA has emerged as promising [13, 30] .
Left atrial appendage closure in the sense of primary primary prevention has the potential to avoid future strokes in case new-onset AF goes undetected on top of the potential to avoid major bleeding in case a patient requires COA for AF during follow-up. However as is inherent to every preventive intervention, the risk and cost of the combined and partially preventive intervention may become unjustified, in case AF never develops during follow-up. This concern is alleviated by the safety of such an approach which is apparent from these data.
Limitations of the study
The study has several limitations. It is a retrospective study and not a randomized trial and therefore selection bias is evident. The sample size is small. HAS-BLED score 0.85 ± 1.1
Atrial rhythm (including history)
Atrial fibrillation (paroxysmal or permanent) 0 (0%)
Atrial flutter 0 (0%)
Clinical features
Prior ischemic stroke 3 (23%)
Coronary artery disease 0 (0%) Valvular heart disease 0 (0%)
Renal function (mean eGFR, in ml/min/1.73 m 2 ) 97 ± 24
Anti-thrombotic therapy prior to laac
Acetylsalicylic acid 3 (23%)
Platelet inibitors other than acetylsalicylic acid 0 (0%)
Chronic oral anticoagulation 0 (0%)
Echocardiographic data
Systolic left ventricular ejection fraction [%] 65 ± 2
Left atrial diameter (PLAX echo, mm) 42 ± 5
Values are n (%) or mean ± standard deviation; eGFR -estimated glomerular filtration rate; PLAX -parasternal long axis Table 2 . Intervention (n = 13). Values are number (%) or mean ± standard deviation Table 4 . Clinical follow-up (n = 13).
Procedural characteristics
Long-term clinical follow-up 13 (100%)
Duration from procedure (years) 2.0 ± 0.8
Antithrombotic therapy
Acetylsalicylic acid 
